Remdesivir As the First FDA-approved COVID-19 Treatment: An Updated Review and Meta-analysis .

Remdesivir became the first FDA-approved COVID-19 treatment in late 2020, driven by early RCTs suggesting quicker recovery in hospitalized patients. But when all high-quality evidence is considered, the picture is far more mixed. Large trials such as WHO’s SOLIDARITY study show no meaningful effect on mortality, ventilation, or hospital stay. Smaller trials report modest improvements—mainly a 2–3 day reduction in time to clinical improvement—without affecting survival. Serious adverse events appear slightly less common with remdesivir, but overall benefits are small and uncertain. Emerging evidence underscores that remdesivir is not a cure and offers limited clinical impact, especially once large, pragmatic trials are factored in.